COMMUNIQUÉS West-GlobeNewswire

NDT Pharmaceuticals Inc.’s Wholly Owned Subsidiary, Good Salt Life, Receives Official Green Seal® Certification for Clean Republic Multipurpose Disinfectant
05/02/2026
ATHENS, Ga., Feb. 05, 2026 (GLOBE NEWSWIRE) -- NDT Pharmaceuticals Inc.’s (OTC: NDTP) (“Company”) wholly owned subsidiary, Good Salt Life, announces that its flagship product, Clean Republic Multipurpose Disinfectant (“ [...]
Profusa Announces 1-for-75 Reverse Stock Split
05/02/2026
BERKELEY, California, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer’s, Mood Disorders, TBI & PTSD Care
05/02/2026
New digital health platform being launched in partnership with UCSD allows remote physician-monitored neurotherapy subscription models to expand reach, lower cost, and break down treatment stigma for brain-health [...]
Primmune Therapeutics Appoints Chief Medical Officer and Executive Board Chair; Establishes Melanoma Clinical Study Advisory Board
05/02/2026
Leadership additions strengthen clinical excellence and governance as the company enters its next phase of growth SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Primmune Therapeutics, Inc. , a biotech company harnessing [...]
Alignment Healthcare to Announce Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call Thursday, Feb. 26, 2026
05/02/2026
ORANGE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), will release its fourth quarter and full-year 2025 financial results on Thursday, Feb. 26, 2026, after market close. Following [...]
Proven Senior Care Model Takes Center Stage at the Capitol
05/02/2026
InnovAge PACE leaders and participants meet with lawmakers during critical budget year DENVER, Feb. 05, 2026 (GLOBE NEWSWIRE) -- InnovAge Holding Corp. (“InnovAge”) (Nasdaq: INNV), a leading Program of All-Inclusive [...]
Cabaletta Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
05/02/2026
PHILADELPHIA, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed [...]
University of West England Adopts HeartSciences’ MyoVista Insights™ Platform and MyoVista® wavECG™ Device to Establish ECG Education and Technology Reference Center
05/02/2026
Southlake, TX, Feb. 05, 2026 (GLOBE NEWSWIRE) -- HeartSciences Inc. ( Nasdaq: HSCS; HSCSW ) (“HeartSciences” or the “Company”), a healthcare information technology (“HIT”) company advancing electrocardiography (“ECG” or [...]
EXACT Therapeutics: Exercise of Warrants by GE Medical Holding AB
05/02/2026
GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT [...]
Aclarion Publishes 2026 Shareholder Letter from the Chairman
05/02/2026
Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028 ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026 (GLOBE NEWSWIRE [...]
Aicuris Presents Positive Phase 3 Data for Pritelivir in Immunocompromised Patients with Refractory Herpes Simplex Virus at TANDEM
05/02/2026
Pritelivir met its primary endpoint of superior lesion healing, achieving a 62.7% lesion healing rate compared to 34.0% with standard-of-care therapies (investigator’s choice), resulting in an adjusted treatment [...]
Vistin Pharma ASA (VISTN): Invitation to Q4 2025 conference call
05/02/2026
Oslo, Norway, 5 February 2026 Vistin Pharma ASA will release its fourth quarter and preliminary 2025 results on Thursday 12th of February 2025. Vistin Pharma will host a conference call for all shareholders and [...]
Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of Magilab in Hungary
05/02/2026
Regulated information - inside information Nazareth (Belgium)/Rotterdam (The Netherlands), 5 February 2026 Fagron obtains regulatory clearance for the acquisition of Vepakum in Brazil and completes the acquisition of [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, ICELAND (February 5, 2026) – [...]
Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation
05/02/2026
Oslo, Norway, 5 February 2026 – Zelluna (OSE: ZLNA), a company pioneering allogeneic “off-the-shelf” T-cell receptor-based natural killer (TCR-NK) therapies for the treatment of cancer, invites to a webcast presentation [...]
Biocomposites gains MDR certification for STIMULAN® Rapid Cure and STIMULAN® Kit
05/02/2026
STIMULAN ® certified to be mixed with a combination of Gram-positive and Gram-negative antibiotics STIMULAN ® certified to resolve infection and reduce the need for secondary surgery STIMULAN ® is the only calcium [...]
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
05/02/2026
The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio ® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026 ( [...]
GN Annual Report 2025: Solid execution leading to market share gains, DKK 1.1 billion free cash flow, and a strong foundation for profitable growth in the years ahead
05/02/2026
2025 highlights GN delivered revenue of DKK 16.8 billion with organic revenue growth of -1% (excluding wind-down), The Hearing division took market share – for the 4 th consecutive year – leading to 5% organic revenue [...]
Evogene and Shanghai Lishan Biopharmaceuticals Co. Announce Exclusive Licensing Agreement for BMC128, a Microbiome-Based Therapeutic for Renal and Lung Cancer
05/02/2026
BMC128 was developed by Biomica, Evogene’s subsidiary, and is currently completing Phase 1 clinical study, showing promising early clinical results REHOVOT, Israel and SHANGHAI, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Evogene [...]

Pages